Table 3 Change in Outcome Measures after 8 weeks (Intention-to-treat analysis) (n = 55-60)
Variable | Blend 1 (mean ± SD) | Blend 2 (mean ± SD) | Placebo (mean ± SD) |
|---|---|---|---|
Endothelial Function | Â | Â | Â |
Flow-mediated dilatation, % | 0.70 ± 3.70 | 0.70 ± 3.80 | 0.60 ± 3.70 |
Stimulus-adjusted response measure | -0.02 ± 0.23 | -0.02 ± 0.21 | -0.03 ± 0.21 |
Flow-mediated dilatation, % (acute effects) | 1.1 ± 3.70 | 0.7 ± 3.5 | -0.3 ± 5.4 |
Serum Measures | Â | Â | Â |
Insulin, pmol/L | 68.06 ± 311.83 | 18.06 ± 213.21 | 15.97 ± 202.79 |
Fasting plasma glucose, mmol/L | 0.03 ± 1.44 | 0.16 ± 1.47 | 0.38 ± 1.58 |
Anthropometric Measures | Â | Â | Â |
Body Weight, kg | 0.40 ± 2.20 | 0.30 ± 2.80 | 0.40 ± 2.20 |
Body Mass Index, kg/m2 | 0.10 ± 0.80 | 0.10 ± 1.00 | 0.10 ± 0.80 |
Lipid Panel | Â | Â | Â |
Total Cholesterol, mmol/L | 0.08 ± 0.47 | 0.08 ± 0.60 | 0.03 ± 0.52 |
High Density Lipoprotein (HDL), mmol/L | 0.04 ± 0.17 | 0.04 ± 0.12 | 0.06 ± 0.15 |
Total Cholesterol/HDL | -0.10 ± 0.60 | -0.10 ± 0.80 | -0.30 ± 0.70 |
Triglycerides, mmol/L | 0.02 ± 0.64 | -0.01 ± 0.71 | -0.13 ± 0.68 |
Low Density Lipoprotein (LDL), mmol/L | -0.02 ± 0.53 | 0.08 ± 0.62 | 0.02 ± 0.53 |